Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesKeros Therapeutics Inc

Keros Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
9.54 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
221303
Market Cap
1759.09M

Momentum Score

…

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
9.23
Low
9.72
High
52 Week Price Range
27.02
Low
73.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Keros Therapeutics is a Nasdaq-listed clinical-stage biopharmaceutical company developing therapies for hematologic and related disorders. Its long-term growth may be driven by clinical trial outcomes, regulatory approvals, strategic partnerships and successful commercialization of lead programs. Investors may find the company attractive because positive clinical data could support meaningful commercial opportunities while addressing unmet medical needs.
The most important risks include clinical trial failure, regulatory setbacks, high cash burn with potential shareholder dilution and competition in specialty therapeutics, and investors should monitor trial readouts and financing risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
9.54
Dividend Yield
-
Revenue TTM
0.23M
Revenue Per Share
0.01
Gross Profit TTM
-87.27M
Debt / Equity
0.04
ROE
-39.63%
Net Debt
-316.70M
ROCE
-33.21%
Diluted EPS TTM
-5.18

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -104.68M -56.73M -45.53M -12.34M -1.08M
Net income -104.68M -58.74M -45.36M -12.34M -1.33M
Selling general administrative 27.52M 21.33M 12.80M 3.18M 1.58M
Gross profit - 20.10M - 10.00M 10.00M
Reconciled depreciation 0.67M 0.38M 0.28M 0.21M 0.15M
Ebit -114.79M -56.37M -46.66M -10.56M -1.32M
Ebitda -104.68M -56.73M -45.53M -9.80M -1.17M
Depreciation and amortization 10.11M -0.36M 1.13M 0.77M 0.15M
Non operating income net other 10.11M -0.36M 1.13M - -
Operating income -114.79M -56.37M -46.66M -10.56M -1.69M
Other operating expenses 107.71M 76.47M 44.20M 20.00M 11.32M
Interest expense 0.00M 0.00M 0.01M 0.01M 0.01M
Tax provision 0.00M 2.01M -0.17M 0.00M 0.26M
Interest income - - - 2.57M 0.04M
Net interest income -0.00M -0.00M -0.01M -0.01M 0.01M
Income tax expense 0.00M 2.01M -0.17M 0.01M 0.26M
Total revenue 0.00M 20.10M 0.00M 10.00M 10.00M
Total operating expenses 107.71M 76.47M 44.20M 20.00M 11.32M
Total other income expense net 10.11M -0.36M 1.12M -1.77M 0.24M
Net income from continuing ops -104.68M -58.74M -45.36M -12.34M -1.33M
Net income applicable to common shares -104.68M -58.74M -45.36M -14.14M -2.35M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 370.02M 306.78M 255.25M 269.44M 10.96M
Other current assets 1.00M 6.72M 0.34M 0.16M 0.23M
Total liab 37.81M 29.36M 12.08M 7.72M 5.50M
Total stockholder equity 332.21M 277.42M 243.17M 261.72M 5.45M
Deferred long term liab - 0.40M - - -
Other current liab 0.67M 12.75M 0.20M 0.22M 0.11M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -381.43M -228.43M -123.75M -65.01M -19.65M
Other liab - - - 0.06M 0.12M
Other assets - 3.44M 1.41M 0.99M 0.12M
Cash 331.15M 279.05M 230.04M 265.88M 7.02M
Total current liabilities 24.37M 16.55M 11.85M 7.18M 4.49M
Current deferred revenue 17.25M - 7.13M 4.39M 1.92M
Net debt -316.70M -265.78M -228.95M -264.98M -5.75M
Short term debt 1.00M 0.46M 0.86M 0.42M 0.38M
Short long term debt total 14.44M 13.27M 1.09M 0.90M 1.27M
Other stockholder equity 713.64M 505.86M 366.93M 326.73M 25.10M
Property plant equipment - 2.02M 1.33M 1.60M 1.91M
Total current assets 347.29M 285.77M 251.44M 267.73M 8.93M
Net tangible assets - 277.42M 243.17M 261.72M -19.45M
Net receivables 1.09M 0.84M 18.00M 0.22M 0.92M
Long term debt - - - - 4.96M
Inventory 14.05M -0.84M 3.06M - 0.76M
Accounts payable 5.45M 3.34M 3.65M 2.15M 2.09M
Accumulated other comprehensive income 0.00M - - -269.44M -0.45M
Common stock total equity - 0.00M 0.00M 0.00M 0.00M
Retained earnings total equity - -228.43M -123.75M -65.01M -
Non currrent assets other 2.05M 3.44M 1.41M 0.12M 0.12M
Non current assets total 22.73M 21.01M 3.81M 1.72M 2.03M
Capital lease obligations 14.44M 13.27M 1.09M 0.90M 1.27M
Long term debt total - - - - 4.96M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1.24M -1.02M -0.29M -0.27M -0.22M
Change to liabilities 4.91M 4.08M 0.06M -8.69M -10.00M
Total cashflows from investing activities -1.24M -1.02M -0.29M -0.27M -0.22M
Net borrowings - - -0.42M - -
Total cash from financing activities 120.31M 28.55M 296.04M 0.01M 11.46M
Change to operating activities -3.28M 0.45M 2.21M 1.96M 17.95M
Net income -104.68M -58.74M -45.36M -12.34M -1.33M
Change in cash 49.01M -34.62M 258.86M -16.25M 18.29M
Begin period cash flow 231.37M 265.99M 7.13M 23.39M 5.10M
End period cash flow 280.38M 231.37M 265.99M 7.13M 23.39M
Total cash from operating activities -70.06M -62.15M -36.89M -16.00M 7.04M
Issuance of capital stock 119.58M 28.17M 299.20M 0.00M 11.50M
Depreciation 0.67M 0.38M 0.28M 0.21M 0.15M
Change to inventory - 1.04M - - -
Change to account receivables 18.00M -18.00M 0.92M -18.00M -18.00M
Sale purchase of stock 120.31M 28.55M 299.01M 0.01M 11.51M
Other cashflows from financing activities 0.73M 0.38M 52.84M -0.27M 11.46M
Change to netincome 18.69M 11.77M 5.91M 2.85M 0.28M
Capital expenditures 1.24M 1.02M 0.29M 0.27M 0.22M
Change receivables 18.00M -18.00M - - -
Cash flows other operating -7.67M -1.62M 1.50M - -
Cash and cash equivalents changes 49.01M -34.62M 258.86M - -
Change in working capital 14.31M -16.07M 2.27M -6.72M 7.95M
Stock based compensation 18.68M 11.72M 4.10M 0.06M 0.08M
Other non cash items 0.95M 0.52M 1.82M 2.79M 0.19M
Free cash flow -71.30M -63.17M -37.19M -16.27M 6.83M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
KROS
Keros Therapeutics Inc		 -
-%		 9.54 - - 13966.49 6.36 11890.58 -11.80
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Keros Therapeutics Inc

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

1050 Waltham Street, Lexington, MA, United States, 02421

617 314 6297

https://www.kerostx.com

141

Name Title Year Born
Dr. Jasbir S. Seehra Ph.D. Pres, CEO, Treasurer, & Director 1956
Mr. Keith C. Regnante MBA Chief Financial Officer 1970
Dr. Jennifer Lachey Ph.D. Chief Scientific Officer 1973
Mr. Christopher Rovaldi M.Sc. Chief Operating Officer 1974
Ms. Esther Cho J.D. Head of Legal & Corp. Sec. NA
Ms. Robin Wagner VP of HR NA
Dr. Simon Cooper MBBS Chief Medical Officer 1970
Dr. Jasbir S. Seehra Ph.D. President, CEO, Treasurer, & Director 1956
Mr. Christopher Rovaldi M.Sc. Chief Operating Officer 1975
Ms. Esther Cho J.D. Senior VP, General Counsel & Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…